These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15621220)

  • 21. An epidemiological survey of overactive bladder symptoms in Japan.
    Homma Y; Yamaguchi O; Hayashi K;
    BJU Int; 2005 Dec; 96(9):1314-8. PubMed ID: 16287452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lower urinary tract symptoms in women.
    Milsom I
    Curr Opin Urol; 2009 Jul; 19(4):337-41. PubMed ID: 19444118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
    Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
    J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stating the case for overactive bladder: a nurse practicioner's perspective.
    Newman DK
    J Am Acad Nurse Pract; 2004 Oct; 16(10 Suppl):1-3. PubMed ID: 15543925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overactive bladder significantly affects quality of life.
    Abrams P; Kelleher CJ; Kerr LA; Rogers RG
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S580-90. PubMed ID: 11183901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The overactive bladder: Epidemiology and morbidity.
    Tyagi S; Thomas CA; Hayashi Y; Chancellor MB
    Urol Clin North Am; 2006 Nov; 33(4):433-8, vii. PubMed ID: 17011378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
    Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X
    Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic considerations in overactive bladder.
    Hu TW; Wagner TH
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S591-8. PubMed ID: 11183902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries.
    Irwin DE; Milsom I; Kopp Z; Abrams P; Cardozo L
    BJU Int; 2006 Jan; 97(1):96-100. PubMed ID: 16336336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS.
    Coyne KS; Wein AJ; Tubaro A; Sexton CC; Thompson CL; Kopp ZS; Aiyer LP
    BJU Int; 2009 Apr; 103 Suppl 3():4-11. PubMed ID: 19302497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower urinary tract symptoms in men and women without underlying disease causing micturition disorder: a cross-sectional study assessing the natural history of bladder function.
    Araki I; Zakoji H; Komuro M; Furuya Y; Fukasawa M; Takihana Y; Takeda M
    J Urol; 2003 Nov; 170(5):1901-4. PubMed ID: 14532803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The overactive bladder: an overview for primary care health providers.
    Wein AJ; Rovner ES
    Int J Fertil Womens Med; 1999; 44(2):56-66. PubMed ID: 10338262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The total economic burden of overactive bladder in the United States: a disease-specific approach.
    Onukwugha E; Zuckerman IH; McNally D; Coyne KS; Vats V; Mullins CD
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S90-7. PubMed ID: 19355803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The economic impact of overactive bladder syndrome in six Western countries.
    Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
    BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Overactive bladder syndrome. How to manage it].
    Tanaka H; Mitsui T; Ameda K; Kobayashi S; Nonomura K
    Hokkaido Igaku Zasshi; 2009 Mar; 84(2):73-6. PubMed ID: 19364048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ["Pathophysiology and treatment of the overactive bladder"].
    Yokoyama O
    Hinyokika Kiyo; 2005 Sep; 51(9):599-601. PubMed ID: 16229372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of overactive bladder, stress and mixed urinary incontinence on quality of life in Thai postmenopausal women.
    Bunyavejchevin S
    J Med Assoc Thai; 2006 Mar; 89(3):294-8. PubMed ID: 16696411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.